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Abstract
Introduction Cytokines produced by spinal cord glia after
peripheral injuries have a relevant role in the maintenance of pain
states. Thus, while IL-1β is overexpressed in the spinal cords of
animals submitted to experimental arthritis and other chronic
pain models, intrathecal administration of IL-1β to healthy
animals induces hyperalgesia and allodynia and enhances wind-
up activity in dorsal horn neurons.
Methods To investigate the functional contribution of glial cells
in the spinal cord nociceptive transmission, the effect of
intrathecally administered IL-1β was studied in both normal and
adjuvant-induced arthritic rats with or without glial inhibition.
Four weeks after induction of monoarthritis, rats were treated
with the glial cell inhibitor propentofylline (10 μg i.t. daily during
10 days) and submitted to a C-fiber-mediated reflex paradigm
evoked by single and repetitive (wind-up) electric stimulation.
Results Both the propentofylline treatment and the
monoarthritic condition modified the stimulating current required
for threshold activation of C reflex responses. Intrathecal IL-1β
increased spinal cord wind-up activity in normal and
monoarthritic rats without propentofylline pre-treatment, but
resulted in decreased wind-up activity in normal and
monoarthritic propentofylline-treated animals. Intrathecal saline
did not produce any effect. Thus, glial inactivation reverted into
inhibition the excitatory effect of IL-1β on spinal cord wind-up,
irrespective of the normal or monoarthritic condition of rats.
Conclusions The results suggest that the excitatory effect of
nanomolar doses of IL-1β on spinal wind-up in healthy rats is
produced by an unidentified glial mediator, while the inhibitory
effects of IL-1β on wind-up activity in animals with inactivated
glia resulted from a direct effect of the cytokine on dorsal horn
neurons. The present study failed to demonstrate a differential
sensitivity of normal and monoarthritic rats to IL-1β
administration into the spinal cord and to disruption of β glial
function, as both normal and monoarthritic animals changes
wind-up activity in the same direction after propentofylline
treatment, suggesting that after glial inhibition normal and
monoarthritic animals behave similarly relative to the capability of
dorsal horn neurons to generate wind-up activity when
repeatedly stimulated by C-fibers.
Introduction
Rheumatoid arthritis remains a major health problem world-
wide, with a prevalence that may amount to one case per 100
people depending on the geographical area of the world con-
sidered [1]. Among other major impairing health problems
associated with rheumatoid arthritis, pain emerges as the most
commonly reported and prevalent disabilitating condition, but
current therapies are still suboptimal. One reason for this,
among other factors, may be that current therapies for rheuma-
toid arthritis do not include glial cells as a target for the origin
and/or maintenance of pain. In this regard, preclinical studies
have shown that adjuvant-induced arthritic rats, a widely used
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animal model of human rheumatoid arthritis, exhibited glial acti-
vation with increased mRNA and protein expressions of both
IL-1 and TNFα in the spinal cord [2]. Interestingly, disruption
of glial activation in these animals by intrathecal injection of the
glial metabolic inhibitor fluorocitrate, reversibly suppressed
thermal hyperalgesia and mechanical allodynia evoked in
arthritic rats [3], pointing to a functional role of upregulated
glial products in arthritic pain, such as IL-1 and TNFα.
The role of glial cells in the pathogenesis of chronic pain is
beginning to be understood. Following inflammation and dam-
age of peripheral tissues, the spinal cord responds with a
robust glial reaction characterized by proliferation, hypertro-
phy, decreased ramification, and upregulated expression of
pro-inflammatory cytokines such as IL-1β and TNF-α. This sug-
gests that some spinal cytokines of glial origin are involved in
the central mechanisms underlying the maintenance and exag-
geration of pain states [4-7]. Further support to this idea is pro-
vided by studies showing that intrathecal administration of IL-
1 and TNFα in healthy rodents induces hyperalgesia and allo-
dynia [8-13], and enhances both the acute response and the
wind-up activity of dorsal horn neurons [14,15].
In order to study the contribution of glial activation and the
associated upregulated expression of IL-1β o n s p i n a l  co r d
nociceptive transmission in arthritic rats, we used the com-
pound propentofylline (3,7-dihydro-3-methyl-1-(5-oxohexyl)-7-
propyl-1H-purine-2,6-dione) to disrupt glial activation. This
compound is an ethylxanthine derivative previously found to
attenuate astrocytic activation in a rodent model of ischemia
[16]. Systemic application of propentofylline has been found
to revert thermal hyperalgesia [17] and mechanical allodynia
induced by peripheral nerve injury [17,18], while intrathecal
administration of propentofylline exhibited antiallodynic prop-
erties in rat models of neuropathic pain [19] and attenuated
vincristine-induced peripheral neuropathy [20]. Thus, in the
current study we examined if propentofylline administration to
adjuvant-induced arthritic and healthy control rats could alter
the spinal cord nociceptive transmission to single and repeti-
tive (wind-up) stimulation, and modify the pronociceptive
effect of intrathecal IL-1β on the electrophysiological parame-
ters. This was carried out by comparing in propentofylline- and
saline-treated rats, the effect of intrathecally administered IL-
1β on single integrated C-reflex and its effect on the potentia-
tion of the responses evoked by repetitive electric stimulation
of the sural nerve receptive field (wind-up). As previously
reported, wind-up activity in dorsal horn neurons is a C-fiber-
mediated synaptic potentiation phenomenon of particular
importance for the development and maintenance of chronic
pain [21], but the role of glia and cytokines on wind-up activity
in arthritic animals has received little attention.
Materials and methods
Animals
This investigation was performed following protocols
approved by the Animal Care and Use Committee of the Uni-
versity of Santiago in Chile and was also in accordance with
the ethical standards for investigations of experimental pain in
animals of The Committee for Research on Ethical Issues of
the International Association for the Study of Pain [22]. Exper-
iments were performed in 32 normal (N) and 32 monoarthritic
(M) Sprague-Dawley rats weighing 280 to 320 g. Monoarthri-
tis was induced by injecting 0.05 ml of complete Freund's
adjuvant into the right tibio-tarsal joint under brief halothane
anesthesia. Complete Freund's adjuvant was prepared as
described by Butler and colleagues [23]. Control rats were
given intra-articular injections (right tibio-tarsal joint) of 0.05 ml
of the vehicle used to suspend mycobacteria. Animals were
housed five per cage under standard laboratory conditions
and were given food and water ad libitum. With the purpose
of knowing the monoarthritic and hyperalgesic condition of the
rats, we measured the circumference of the injected tibio-tar-
sal joint (from 2.75 ± 0.25 cm [mean ± standard error of the
mean] to 4.3 ± 0.3 cm after four weeks) as well as the vocali-
zation threshold (225 ± 12.5 g to 172 ± 13 g after four weeks)
to graded paw pressure (Ugo Basile analgesiameter, Comerio
VA, Italy).
Four weeks after injecting the tibio-tarsal joint, once a stable
vocalization threshold value to graded paw pressure was
determined, eight monoarthritic and eight normal rats were
given once daily intrathecal injections of 10 μg propentofylline
(P) in 10 μl saline for 10 days. This 10-day treatment has been
shown to produce glial inhibition, as revealed by a decrease in
both CR3/CD11b and glial fibrillary acidic protein, which are
microglial and astrocytic activation markers, respectively, and
to attenuate hyperalgesia induced by nerve transection in rats
[19,24]. Eight monoarthritic and eight normal additional rats
receiving intrathecal injections of saline (S) for 10 days served
as controls. Thus, the four groups of rats were: NP rats which
were normal rats receiving intrathecal propentofylline; NS rats
which were normal rats receiving intrathecal saline; MP rats
which were monoarthritic rats receiving intrathecal propen-
tofylline; and MS rats which were monoarthritic rats receiving
intrathecal saline. All intrathecal injections (10 μl volume) were
given to unanesthetized rats by means of direct percutaneous
injection at the L5 to L6 interspace using a 0.5 inch 26-gauge
hypodermic needle connected to a Hamilton syringe [25], and
correct subarachnoid positioning of the tip of the needle was
verified by the generation of a tail-flick. Afterwards, at day 11,
the animals were submitted to the electrophysiological study.
All the experiments were performed blind (LC).
C-fiber evoked nociceptive reflex
The C-reflex, elicited in the right hindlimb of urethane anesthe-
tized rats (1.2 g/kg intraperitoneally), was recorded as
described previously [15,26]. Briefly, rectangular electricAvailable online http://arthritis-research.com/content/11/4/R105
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pulses of supramaximal strength and 2 ms' duration were
applied every 10 seconds to the sural nerve receptive field by
means of two stainless steel needles inserted into the skin of
toes four and five (Grass S11 stimulator equipped with a
Grass SIU 5 stimulus isolation unit and a Grass CCU 1A con-
stant current unit, Astro-Med, Inc., West Warwick, RI, USA).
The C-fiber-evoked reflex response was recorded from the
ipsilateral biceps femoris muscle by utilizing another pair of
stainless steel needles. After amplification (Grass P511
preamplifier; Astro-Med, Inc., West Warwick, RI, USA), the
electromyographic responses were digitized at 100 KHz and
integrated in a time-window from 150 to 450 ms after the stim-
ulus by a Powerlab ML 820 instrument (ADInstruments, Castle
Hill, NSW, Australia). Once stable C-reflex responses were
obtained, the stimulus strength was lowered and the current
required for threshold activation of the C-reflex determined.
The values of current in mA (Table 1) obtained in the different
groups of animals (NS, NP, MS, and MP groups) were stored
to be analyzed later by means of a two-way analysis of variance
(ANOVA; Prism 3.0, GraphPad Software Inc., San Diego, CA,
USA). Integrated C-reflex responses, evoked by single stimuli
with two times the intensity of the threshold stimulating cur-
rent, were then recorded. Afterwards, trains of 12 stimuli each
at 1 Hz were delivered to the toes in order to develop wind-up
activity. In the C-reflex paradigm, wind-up consists of a stimu-
lus frequency-dependent remarkable increment of the electro-
myographic integrated response [11]. All responses were
stored on hard disk for later analysis. Least square regression
lines were fitted among experimental points showing only
incremental trend (prior to wind-up saturation at the sixth or
seventh stimulus), discarding the remaining points (Origin 6.0
software, Microcal Software, Inc., Northampton, MA, USA), as
described elsewhere [11]. The slopes of the regression lines
represent wind-up scores.
Data analysis
In all animals the experiments began with the measurement of
the current required for threshold activation of the C-reflex in
each of four groups of animals. Two-way ANOVA followed by
the Bonferroni multiple comparisons test were used to identify
the drug treatment (propentofylline) and/or the monoarthritis
as factors influencing this parameter in normal and monoar-
thritic rats treated with propentofylline. Afterwards, a basal
recording of both integrated C-reflex responses and wind-up
activity prior to the intrathecal administration of recombinant
IL-1β (2 ng/10 μl, equivalent to 11.4 nM) or saline (10 μl). This
intrathecal dose of IL-1β has been shown to increase C-fiber
evoked responses and wind-up activity in spinal cords of nor-
mal rats [8,9]. The effects of IL-1β or saline on the integrated
C-reflex responses and wind-up scores were assessed 10, 20
and 40 minutes post-injection, and the results expressed as
time-course of the percent change induced. Statistically signif-
icant effects of IL-1β within groups were identified by one-way
ANOVA, followed by the Dunnett multiple comparisons test.
To appreciate the global effect of IL-1β on the complete period
of testing, the area under curves (AUCs) for both the inte-
grated responses and wind-up activity were calculated from
time zero to 40 minutes (period of testing) by using the Micro-
cal Origin 6.0 software (Microcal Software, Inc., Northampton,
MA, USA) and plotted in terms of percent variation. Two-way
ANOVA followed by the Bonferroni multiple comparisons test
were used to identify the drug treatment (propentofylline) and/
or the pain model (monoarthritis) as factors influencing the
effect of IL-1β on the integrated C-reflex responses and wind-
up scores. When a P value in the ANOVAs was less than 0.05,
the Bonferroni post-hoc multiple comparisons test was used
with a confidence interval of 95% (Prism 3.0, GraphPad Soft-
ware Inc., San Diego, CA, USA).
Results
Application of single constant electric pulses to toes, at 0.1
Hz, evoked C-fiber-mediated reflex responses in the ipsilateral
biceps femoris muscle in both normal (N) and monoarthritic
(M) rats, with chronic propentofylline (P) or saline (S) pretreat-
ment. The stimulating current required for threshold activation
of the C-reflex in each of four groups of animals is shown in
Table 1. It can be observed that NS rats required a stimulating
current of 6.3 ± 0.4 mA for threshold activation of the C-reflex,
while a significantly greater stimulating current of 8.2 ± 0.5 mA
(P < 0.01) was necessary to evoke threshold C-reflexes in nor-
mal-propentofylline (NP) animals. In MS rats the stimulating
current required for threshold activation of the C reflex was 3.7
± 0.6 mA (P < 0.01 with respect to NS rats), whereas MP ani-
mals required 7.5 ± 0.7 mA (P < 0.01 with respect to MS ani-
mals).
Table 1
Stimulating current (mA) required for threshold activation of C-
fiber evoked reflex responses in normal and monoarthritic rats 
treated with propentofylline (10 μg/10 μl daily) or saline (10 μl 
daily) during 10 days
Saline treated Propentofylline treated
Normal 6.3 ± 0.4 8.2 ± 0.5*
Monoarthritic 3.7 ± 0.6# 7.5 ± 0.7*
Values are means ± standard error the mean of stimulating current 
required (in mA) in the NS, MS, NP and MP groups. Two-way 
analysis of variance (ANOVA) identified the propentofylline treatment 
(P ANOVA < 0.0001, F = 25.79) and the monoarthritic condition (P 
= 0.0065, F = 8.64) as significant factors influencing the stimulating 
current required for threshold activation of the C-reflex. No 
propentofylline treatment × monoarthritic condition interaction was 
observed (P ANOVA = 0.1016, F = 2.87). Significant differences (P 
< 0.01) between propentofylline- and saline-treated groups are 
denoted by asterisks, while significant differences between 
monoarthritic and normal groups (P < 0.01) are indicated by the 
superscript # (according to the Bonferroni post hoc test). n = 8 
animals for each group.
NP = normal rats receiving intrathecal propentofylline; NS = normal 
rats receiving intrathecal saline; MP = monoarthritic rats receiving 
intrathecal propentofylline; MS = monoarthritic rats receiving 
intrathecal saline.Arthritis Research & Therapy    Vol 11 No 4    Constandil et al.
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Intrathecal administration of a single dose of 2 ng of IL-1β to
normal or to monoarthritic rats with or without propentofylline
treatment, did not produce significant changes either in the
time-course of integrated C-reflex responses (Figure 1b) or in
AUCs during the complete 40-minute period of testing (Figure
1d). Intrathecal saline was also ineffective in these respects
(Figures 1a and 1c). Representative traces for the effects of IL-
1β administration on C-reflex responses are shown in Figure
2b.
Application of 12 successive constant electric pulses with
two-fold threshold intensity, at 1 Hz, induced spinal wind-up in
all groups of rats, as revealed by the gradual but remarkable
increase of the integrated C-reflex activity generated by the
repetitive stimuli. Figure 2a shows the potentiation of the C-
reflex (wind-up) taken from a representative experiment as the
stimulating train progresses from the first to the seventh pulse.
Intrathecal administration of a single dose of 2 ng of IL-1β to
the NS group resulted in about 80% increase of wind-up activ-
ity 20 minutes after the injection (Figure 3b, P < 0.05). In con-
trast, 2 ng of IL-1β intrathecally administered to the NP group
produced around 30% reduction in wind-up scores 20 to 40
minutes after injection (Figure 3b, P < 0.05). Administration of
IL-1β intrathecally to monoarthritic rats produced similar
effects on wind-up activity to that induced in normal animals
(Figure 3b), that is a significant increase (110% increase) of
wind-up scores in the MS group but a decrease (55% reduc-
tion) of wind-up scores in the MP group 20 and 40 minutes
Figure 1
Effect of IL-1β on C-reflex integrated activity in propentofylline-and saline-treated normal and monoarthritic rats (NS, MS, NP, and MP groups) Effect of IL-1β on C-reflex integrated activity in propentofylline-and saline-treated normal and monoarthritic rats (NS, MS, NP, and MP groups). (a) 
Time course of integrated C-reflex responses (% change) 10, 20 and 40 minutes after administration of saline intrathecal. (b) Time course of inte-
grated C-reflex responses (% change) 10, 20 and 40 minutes after administration of 2 ng IL-1β intrathecally. The arrow indicates injection of saline 
or IL-1β at zero time. Values are means ± standard error of the mean (SEM). n = 8 rats in all groups. One-way analysis of variance (ANOVA) did not 
detect significant intra-group changes in either group after intrathecal saline or after IL-1β. (c) Global effect of saline intrathecally and (d) 2 ng IL-1β 
intrathecally on integrated C-reflex responses on the 40-minute period of testing, as revealed by percent change of area under the curves (AUCs). 
Values are means ± SEM. n = 8 rats in all groups. Two-way ANOVA detected that neither the propentofylline-treatment, nor the monoarthritic condi-
tion, nor the combination of propentofylline-treatment and monoarthritis affected the AUCs scores significantly or modified the response to saline 
intrathecally or to IL-1β intrathecally. NP = normal rats receiving intrathecal propentofylline; NS = normal rats receiving intrathecal saline; MP = 
monoarthritic rats receiving intrathecal propentofylline; MS = monoarthritic rats receiving intrathecal saline.Available online http://arthritis-research.com/content/11/4/R105
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after injection of the cytokine (P < 0.05). Intrathecal saline did
not produce any significant effect in wind-up of either normal
or monoarthritic animals (Figures 3a and 3c). Accordingly,
upon analyzing the global effect of IL-1β on wind-up activity
during the complete 40-minute period of testing (% change of
AUCs), two-way ANOVA identified the propentofylline treat-
ment, but not the monoarthritic condition, as a factor influenc-
ing the effect of IL-1β on wind-up activity in both normal and
monoarthritic rats (Figure 3d; P ANOVA < 0.0001; P < 0.01,
Bonferroni post hoc test). No interaction of the two factors
(propentofylline treatment × monoarthritic condition) was
detected, meaning that the propentofylline treatment modified
in a similar way the wind-up change elicited by IL-1β adminis-
tration, irrespective the normal or monoarthritic condition of
rats. Representative traces for the effects of IL-1β administra-
tion on wind-up activity are shown in Figure 2c.
Figure 2
Representative traces showing the effect of a stimulating train and of IL-1β on C-reflex responses Representative traces showing the effect of a stimulating train and of IL-1β on C-reflex responses. (a) Representative traces showing C-reflex poten-
tiation (wind-up) as the stimulating train progresses from the first to the seventh stimulus number. After the seventh stimulus the potentiation reach a 
plateau and C-reflex response does not grow (not shown). (b) Representative traces of C-reflex responses taken from one animal per group (NS, 
MS, NP, and MP) showing pre-drug traces (left side) and 20 minutes post IL-β traces (right side). (c) Representative traces of potentiated C-reflex 
responses (wind-up) taken from one animal per group (NS, MS, NP and MP): left side = pre-drug traces; right side = 20 minutes post IL-β potenti-
ated traces. Calibration bars are shown at the bottom. NP = normal rats receiving intrathecal propentofylline; NS = normal rats receiving intrathecal 
saline; MP = monoarthritic rats receiving intrathecal propentofylline; MS = monoarthritic rats receiving intrathecal saline.Arthritis Research & Therapy    Vol 11 No 4    Constandil et al.
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Discussion
Our results show that in the rat, a 10-day period of treatment
with propentofylline intrathecally did not block the ability of
dorsal horn neurons to respond to C-fiber nociceptive stimula-
tion and to develop wind-up activity during repetitive C input,
but increased the threshold for the triggering of C-fiber-
dependent nociceptive reflexes, thus suggesting that glial
cells of the spinal cord dorsal horn play some role in pain trans-
mission conveyed by the C-fiber population even in the
absence of injury in peripheral sensitive nerves and/or in cen-
tral spinal cord neurons. On the other hand, adjuvant-induced
arthritis decreased the stimulating threshold to evoke C-reflex
responses, thus confirming previous observations [11]. Inter-
estingly, intrathecal propentofylline treatment increased the
threshold for electrical activation of C-reflexes in monoarthritic
rats to values found in normal rats, thus pointing to a role of
Figure 3
Effect of IL-1β on spinal cord wind-up activity in propentofylline- and saline-treated normal and monoarthritic rats (NS, MS, NP and MP groups) Effect of IL-1β on spinal cord wind-up activity in propentofylline- and saline-treated normal and monoarthritic rats (NS, MS, NP and MP groups). (a) 
Time course of wind-up scores (% change) 10, 20 and 40 minutes after administration of saline intrathecally. One-way analysis of variance (ANOVA) 
did not detect significant intra-group changes in either group after intrathecal saline. The arrow indicates injection of saline at zero time. Values are 
means ± standard error of the mean (SEM). n = 8 rats in all groups. (b) Time course of wind-up scores (% change) 10, 20 and 40 minutes after 
administration of 2 ng IL-1β intrathecally. The arrow indicates injection of IL-1β at zero time. Values are means ± SEM. n = 8 rats in all groups. Values 
are means ± SEM. n = 8 rats in all groups. Intra-group analyzes by one-way ANOVA detected significant wind-up increases in the NS and MS 
groups after intrathecal IL-1β (NS group: P ANOVA = 0.0403, F = 3.154; MS group: P ANOVA < 0.0004, F = 8.363), and significant wind-up 
decreases in the NP and MP groups after intrathecal IL-1β (NP group: P ANOVA = 0.0407, F = 3.147; MP group: P ANOVA = 0.0135, F = 4.253). 
Significant changes after IL-1β administration are denoted by the asterisk (*P < 0.05, Dunnett post hoc test). (c) Global effect of saline intrathecally 
on C-reflex wind-up activity on the 40-minute period of testing, as revealed by percent change of area under the curves (AUCs). Values are means ± 
SEM. n = 8 rats in all groups. Two-way ANOVA detected that neither the propentofylline-treatment, nor the monoarthritic condition, nor the combina-
tion of propentofylline-treatment and monoarthritis affected the AUC scores significantly or modified the response to saline intrathecally. (d) Global 
effect of 2 ng IL-1β intrathecally on C-reflex wind-up activity on the 40-minute period of testing, as revealed by percent change of AUCs. Values are 
means ± SEM. n = 8 rats in all groups. Two-way ANOVA identified the propentofylline treatment (P ANOVA < 0.0001, F = 46.91), but not the 
monoarthritic condition (P ANOVA = 0.5799, F = 0.31), as a factor influencing the effect of IL-1β on wind-up activity. # indicates statistically signifi-
cant difference (P < 0.01, Bonferroni post hoc test) when comparing propentofylline-treated animals (NP and MP) against the respective saline-
treated animals (NS and MS). NP = normal rats receiving intrathecal propentofylline; NS = normal rats receiving intrathecal saline; MP = monoar-
thritic rats receiving intrathecal propentofylline; MS = monoarthritic rats receiving intrathecal saline.Available online http://arthritis-research.com/content/11/4/R105
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some spinal glial products in the maintenance of a low excita-
tion threshold for C-reflex activation during arthritis. As it is
known that propentofylline affects glial activation and thereby
the production of glial proinflammatory cytokines, but it seems
propentofylline is unable to produce a direct effect on neurons.
The present results also showed that intrathecal administra-
tion of IL-1β increased synaptic potentiation to a train of stimuli
(wind-up) in the spinal cords of both normal and monoarthritic
rats, while not affecting the spinal cord transmission of spinal
C-reflex to a single stimulus. This observation suggests that IL-
1β of glial origin could play a role in the maintenance of chronic
pain by increasing wind-up activity in dorsal horn nociceptive
neurons via direct excitation of IL-1 receptors existing in pres-
ynaptic afferent terminals and/or second-order neurons [27],
or indirectly by acting on glial cells. Interestingly, the present
results demonstrated that the intrathecal propentofylline pre-
treatment turned the excitatory effect of IL-1β on spinal cord
wind-up activity into inhibition, in both normal and monoar-
thritic rats. This observation suggests the exogenous IL-1β did
not act directly on IL-1 receptors of dorsal horn neurons to
enhance wind-up activity, but probably on glial IL-1 receptors,
thereby inducing the release of a glial mediator responsible for
the excitatory effects observed in saline-treated normal and
monoarthritic rats. In this respect, there is a variety of potential
glial mediators that can fulfill an excitatory role on dorsal horn
nociceptive neurons [3]. Firstly, the excitatory amino acid
glutamate, which is known to be released from spinal cord glia
and play a major role in wind-up elicitation. Second, the ubiq-
uitous molecule nitric oxide, which has been directly impli-
cated in glutamate release from primary nociceptive afferent
terminals. Third, other cytokines, such as TNF-α, which have
been described as having excitatory activity in dorsal horn
cells [12]. Fourth, the glial mediator D-serine, which binds to
the glycine site of the NMDA receptor and has been shown to
enhance the C-response of dorsal horn neurons [28] and facil-
itation of the tail-flick reflex [29] in normal rats. All these medi-
ators can potentially be released from glia after glial cell
stimulation with IL-1β, provided glial cells are intact.
In contrast, the inhibitory effect of intrathecal IL-1β on wind-up
activity in propentofylline-treated rats is probably the result of
a direct inhibitory effect of the cytokine on dorsal horn neu-
rons, which would be observed only when glial cells are inhib-
ited by propentofylline. In this regard, inhibitory neuronal
effects of IL-1β have been shown in warm-sensitive [30] and
glucose-sensitive [31] neurons of the hypothalamus, while
both inhibitory and excitatory effects of IL-1β have been
observed on neocortical neurons [32]. Rapid (minutes) inhibi-
tory effects of IL-1β on firing rate of hypothalamic neurons
have been shown to be dependent on activation of protein
kinase Src downstream of the association of the cytosolic
adaptor protein MyD88 to the IL-1 receptor [33].
Using patch-clamp techniques it has been demonstrated that
at physiologic picomolar concentrations IL-1β exerted excita-
tory effects on central neurons via activation of a non-selective
cationic current, while at pathologic nanomolar levels IL-1β
inhibited central neurons by inducing membrane hyperpolari-
zation [34]. Other patch-clamp studies demonstrated that
nanomolar concentrations of IL-1β decreased inward calcium
depolarizing currents in hippocampal neurons [35] and inward
sodium depolarizing currents in retinal ganglion cells [36],
which may give a mechanistic support to the inhibitory effect
of the intrathecally-administered nanomolar dose of IL-1β on
C-reflex wind-up evoked in propentofylline-treated animals.
This also may explain the results that show that administration
of high intrathecal doses of IL-1β (over 10 ng IL-1 intrathecal)
could produce anti-nociception in a rat model of peripheral
inflammatory pain [37]. As a whole, the present observations
do not support a direct excitatory role for glial IL-1β on the
nociceptive processing of spinal cord neurons to repetitive C
input but an indirect one via the release of other glial excitatory
products (i.e. glutamate), IL-1β being rather involved in the
fueling of the glial inflammatory response as part of a glial auto-
crine loop that may occur during chronic arthritic pain. In these
conditions, any direct inhibitory effect of IL-1β on dorsal horn
neurons would be exceeded by the excitatory effect of glial
excitatory products on neuronal activity, a situation not possi-
ble when glia is inhibited by propentofylline.
Finally, the present study failed to demonstrate a differential
sensitivity of normal and monoarthritic rats to IL-1β administra-
tion into the spinal cord, suggesting that adjuvant-induced
arthritis in rat did not result in marked upregulation of glial and/
or neuronal IL-1 receptors. However, alternative explanations
involving high occupancy of upregulated IL-1 receptors by
endogenous IL-1β or by the endogenous IL-1 receptor antag-
onist which could be highly expressed in monoarthritic rats are
also possible. Besides, the present study also failed to demon-
strate a differential response of normal and monoarthritic rats
after disruption of glial function, at least when the animals were
tested to IL-1β challenge, as both normal and monoarthritic
animals changes wind-up activity in the same direction after
propentofylline treatment. This observation suggests that after
glial inhibition, normal and monoarthritic animals behave simi-
larly relative to the capability of dorsal horn neurons to gener-
ate wind-up activity when repeatedly stimulated by C-fibers.
Conclusions
Both the propentofylline treatment and the monoarthritic con-
dition modified the stimulating current required for threshold
activation of C-reflex responses. Intrathecal IL-1β increased
spinal cord wind-up activity in normal and monoarthritic rats
without propentofylline pre-treatment, but resulted in
decreased wind-up activity in normal and monoarthritic pro-
pentofylline-treated animals. Intrathecal saline did not produce
any effect. Thus, glial inactivation reverted to inhibition the
excitatory effect of IL-1β on spinal cord wind-up, irrespective
of the normal or monoarthritic condition of rats. The results
suggest that the excitatory effect of nanomolar doses of IL-1βArthritis Research & Therapy    Vol 11 No 4    Constandil et al.
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on spinal wind-up in healthy rats is produced by an unidenti-
fied glial mediator, while the inhibitory effects of IL-1β on wind-
up activity in animals with inactivated glia might result from a
direct effect of the cytokine on dorsal horn neurons. Finally,
spinal cord glial inhibition results in decreased potentiation of
repetitive nociceptive input, thus suggesting future clinical
applications in arthritic pain once glial inhibitors are available
for human use.
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